Healthcare
Repligen Corporation(RGEN)
Live Price
Offline$130.59
-2.06% today
1Y Change
+2.49%
Window
Jun 23, 2025 โ Jun 1, 2026
- Market Cap
- $6.61B
- Revenue Growth
- +16.4%
- EPS Growth
- +289.1%
- Dividend Yield
- 0.0%
Coverage: 236 bars ยท Jun 23, 2025 โ Jun 1, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Repligen Corporation (RGEN) is a Healthcare stock with a market cap of $6.61B and listed on NASDAQ. The stock last traded around $130.59 and up 2.5% across the available one-year price window (Jun 23, 2025 โ Jun 1, 2026). Baseline metrics include revenue growth of +16.4%, EPS growth of +289.1%, a dividend yield of 0.0%. What stands out right now is revenue +16.4%, EPS +289.1%, free cash flow -34.1% with operating margin 7.6% and ROIC 1.5%. Valuation already assumes a fairly strong business story at P/E 135.5 and price/sales 9.0. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines RGEN price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+16.4% vs +7.6% peer median
Operating Margin
Below sector median
+7.6% vs +19.4% peer median
P/E
Above sector median
135.5 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 5, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +16.4% and EPS at +289.1%, with operating margin around 7.6%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -7.1% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 5, 2026 | โ | +0.1% | -9.6% | โ |
2026 Feb 24, 2026 | +11.4% | -1.9% | -8.6% | -13.6% |
2025 Oct 28, 2025 | +9.5% | -2.0% | -3.1% | +13.3% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
RGEN
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
RGEN Max Drawdown
-40.28%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for RGEN and SPY.
Company Overview
Repligen Corporation
NASDAQ Global Select
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and SpectraFlo dynamic dialysis systems; and ProConnex single-use hollow fiber. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. Repligen Corporation was incorporated in 1981 and is headquartered in Waltham, Massachusetts.
- Leadership
- Olivier Loeillot
- IPO Date
- Apr 29, 1986
- Employees
- 1.8k
- Street Address
- Building 1
- Mailing
- Waltham, MA, 02453
- Region
- Waltham, MA, US
- Reporting Currency
- USD
- Investor Line
- 781 250 0111
- Last Updated
- May 4, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 135.5
- EV/EBITDA
- 38.1
- Price/Sales
- 9.0
- Price/Book
- 3.1
Growth
- Revenue
- +16.4%
- EPS
- +289.1%
- Free Cash Flow
- -34.1%
Profitability
- Gross Margin
- 50.9%
- Operating Margin
- 7.6%
- Net Margin
- 6.6%
- ROE
- 2.4%
- ROIC
- 1.5%
Balance Sheet
- Debt/Equity
- 0.33
- Current Ratio
- 8.37
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.